secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tyra Biosciences, Inc. (TYRA)
CIK:        0001863127
Form:       8-K
Filed at:   2022-05-05T23:59:59+00:00
Accession:  0001193125-22-142331
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tyra Biosciences Q1 net loss $14.8M; cash $292.5M; IND filings on track for 2022
--------------------------------------------------------------------------------

- Net loss of $14.8M in Q1 2022 vs $4.2M in Q1 2021, driven by higher R&D and G&A expenses.
- R&D expense $9.6M (up from $3.5M); G&A expense $5.2M (up from $0.7M).
- Cash and equivalents $292.5M as of March 31, 2022, supporting pipeline into clinical stage.
- IND for TYRA-300 (FGFR3 inhibitor) expected mid-2022; TYRA-200 (FGFR2) IND in H2 2022.
- Pipeline includes programs in achondroplasia, RET, and FGFR4-driven cancers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1863127/000119312522142331/0001193125-22-142331-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1863127/000119312522142331/d350831d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-142331

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer